Panelists discuss how biosimilar manufacturers can increase uptake by ensuring positive financial outcomes for all stakeholders, maintaining strong patient assistance programs, and working closely with health care providers who significantly influence biosimilar implementation.
Manufacturer Partnerships and Biosimilar Value Proposition
Key Themes:
Key Points for Physicians:
Notable Insights:
The operational change management burden for pharmacies transitioning patients between products requires proper incentives to justify the effort.
Clinical Significance: Successful biosimilar implementation requires addressing financial viability across the care continuum while ensuring patient affordability, creating alignment among all stakeholders in the delivery system.
FDA Approves Pegcetacoplan for Rare Kidney Diseases C3G, Primary IC-MPGN in Patients 12 and Older
July 29th 2025The FDA approved pegcetacoplan (Empaveli; Apellis Pharmaceuticals) as the first treatment for patients 12 years and older with the rare, severe kidney diseases C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).
Read More
Gefurulimab for gMG Meets Key End Points in PREVAIL Trial
July 28th 2025The primary endpoint in PREVAIL is Myasthenia Gravis-Activities of Daily Living total score improvement from baseline, and the secondary endpoints are Quantitative Myasthenia Gravis total score and Myasthenia Gravis Composite total score.
Read More